[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"subjective-cognitive-impairment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:subjective-cognitive-impairment":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,57,86,120,160,186,210,235,250,283,313,342,375,397,419],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":35,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100620930","the-brain-health-pro-online-risk-factor-reduction-study-to-prevent-dementia-100620930",false,"NCT07364019","The Brain Health PRO Online Risk Factor Reduction Study to Prevent Dementia","The Brain Health PRO Online Risk Factor Reduction Study for The Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia","BHPROOF","Inclusion Criteria:\n\n* Completion and documentation of the electronic Informed Consent Process (from the participant)\n* Sufficient proficiency in English or French to undergo online assessments and participate in an online educational program.\n* Technical ability to participate in an online educational program and remote assessments (i.e., regularly have access to a computer or tablet with an internet connection; have access to a desktop or laptop computer with an internet connection at least once every 6 months; ability to send and receive emails; ability to complete online assessments)\n* Sufficient vision to participate in an online educational program and complete online cognitive testing\n* Ages 50-80\n* Classified as being at increased risk of dementia based on at least one of the following:\n\n  * First-degree family history of dementia\n  * Education level at or below high school (grade 12 or less)\n  * Self-Reported: Hypertension, Hypercholesterolemia, Body Mass Index \\> 30 kg\u002Fm2 (derived from NIH Metric BMI Calculator), or Physical Inactivity (active is defined as engaging in a minimum of 20- 30 min of physical activity causing sweating and breathlessness, at least 2 times a week)\n\nExclusion Criteria:\n\n* Individuals who have a clinical diagnosis of Dementia (based on self-report)\n* Individuals who are currently participating in or have participated in a past study involving BHPro",true,"ALL","50 Years","80 Years",{"count":22,"type":23},700,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study will recruit participants at risk for dementia to participate in an online educational program called Brain Health PRO (BHPro). The BHPro intervention is designed to address modifiable risk factors for dementia through a 6-month, fully online, educational program conveying the best available evidence for lifestyle changes that can mitigate dementia risk, and foster engagement toward one's own brain health. Achieving lifestyle changes in a diverse Canadian population through online education would be a major achievement in dementia prevention in Canada, with widespread personal and socioeconomic benefits.\n\nEligible participants will be randomly assigned to either start Brain Health PRO immediately or in 6 months (delayed-start control group). All participants will have the opportunity to have access to BHPro for 6 months during the course of the study and will have open access to all content for 12 months following the initial 6-month intervention. Participation will last from 18-24 months depending on group assignment.",[29,30,31,32,33,34],"Dementia Prevention","Subjective Cognitive Impairment","Mild Cognitive Impairment","Cognitive Change","Lifestyle Intervention","Dementia Education",[36,37,38,39,40,41,42,43],"dementia education","at risk for dementia","lifestyle intervention","dementia reduction","dementia risk factor","dementia prevention","cognitive impairment","Alzheimer risk","RECRUITING","2026-05-14",{"date":47,"type":48},"2026-05-19","ACTUAL",{"date":50,"type":48},"2026-05-07",{"date":52,"type":23},"2028-12-31",{"name":54,"class":55},"University of British Columbia","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":24,"phases":66,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":56},"100627231","physiological-effect-of-non-invasive-photobiomodulation-on-cognition-and-mood-in-older-adults-with-subjective-cognitive-impairment-100627231","NCT07445945","Physiological Effect of Non-invasive Photobiomodulation on Cognition and Mood in Older Adults With Subjective Cognitive Impairment","Inclusion Criteria:\n\n* Affirmative responses to two questions on a self-report questionnaire: \"Do you feel your memory is becoming worse?\" \"If so, are you concerned?\"\n\nExclusion Criteria:\n\n* Presence of clinically diagnosed dementia, mild cognitive impairment, depression, post-traumatic stress disorder, obsessive-compulsive disorder, eating disorder(s), schizophrenia, or other psychiatric disorders.\n* History of a manic, hypomanic, or mixed depressive episode.\n* Treatment with electroconvulsive therapy, intravenous and\u002For intranasal ketamine in the 6-weeks prior to study enrolment.\n* History of substance-use disorder in the past 12 months.\n* Presence of current alcohol-use disorder.\n* A positive urine toxicology screen for non-prescribed substance use.\n* A positive pregnancy test at screening.\n* A history of major medical or neurological illness.\n* A history of traumatic brain injury, stroke, seizures, or previous brain surgery.\n* Current use of anti-coagulants.\n* Contraindications to magnetic resonance imaging (MRI) scanning.\n* Being currently involved in other intervention studies.","75 Years",{"count":65,"type":23},80,[26],"Subjective cognitive impairment (SCI) is a non-clinical condition manifesting as a self-reported decline in cognitive function without objective clinical evidence, and is prevalent among older adults and strongly associated with declining mood. This study explores the potential of photobiomodulation (PBM) as a therapeutic intervention for SCI. PBM, using near-infrared light, is a non-invasive neuromodulation approach that has shown promise in improving neuronal function, blood flow, and reducing inflammation in both healthy adults and patients with neurological conditions, including dementia and depression. This study proposes investigating the potential of forehead (tPBM), intranasal (iPBM) and vagal (vPBM) PBM to enhance mood and cognitive function in individuals with SCI as a proof of concept for the future use of PBM as therapy for cognitive decline in general.\n\nThis study will recruit approximately 80 participants with SCI for the study, and the total expected duration of the participant\\'s participation in the study is 5 weeks. The active and sham Neuro 5T device consisting of a headset with a built-in controller, nasal and neck applicators will be used. The nasal and neck applicators each contains a single LED and will be placed into the nostril or neck and secured into place. The headset contains multiple LEDs in a wearable applicator and may be adjusted. The Neuro 5T also contains telemetry features to allow documentation of patient usage of the device. LEDs are semiconductor electronic components that emit light. Participants will be given PBM devices for in-home usage, 2 times a day, 7 days a week, for 5 weeks. Participants will undergo EEG, MRI, cognitive and nasal microbiome assessments before and after the 5-week period.",[69,30],"Subjective Cognitive Decline (SCD)",[71,72,73,74,75],"Photobiomodulation","Light Therapy","Electroencephalography","MRI","Neuromodulation","NOT_YET_RECRUITING","2026-02-25",{"date":79,"type":48},"2026-03-03",{"date":81,"type":23},"2026-06",{"date":83,"type":23},"2028-07",{"name":85,"class":55},"Baycrest",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":18,"minAge":94,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":98,"conditions":99,"keywords":104,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":56},"100623863","the-signature-of-alzheimers-disease-in-subjective-cognitive-decline-100623863","NCT07402161","The Signature of Alzheimer's Disease in Subjective Cognitive Decline","Unraveling the SIGNature of ALzheimer's Disease: Integrating Multimodal Biomarkers Through Machine Learning","SIGN-AL","Inclusion Criteria:\n\n* Clinical diagnosis of SCD according to the SCD-I criteria;\n* Mini-Mental State Examination (MMSE) score greater than 24, adjusted for age and education level;\n* Normal functioning on the Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) scales.\n\nExclusion Criteria:\n\n* History of head trauma;\n* Current neurological and\u002For systemic diseases;\n* Symptoms of psychosis, major depression, or substance use disorder.","18 Years",{"count":96,"type":23},250,"OBSERVATIONAL","This study focuses on improving early detection of Alzheimer's disease (AD) in patients with subjective cognitive decline (SCD), a preclinical stage of cognitive impairment, in the context of emerging disease-modifying therapies (DMTs). Current biomarkers, such as brain MRI, PET scans, and cerebrospinal fluid (CSF) markers, are highly accurate but costly, invasive, and not widely accessible.\n\nThe study aims to provide cost-effective, scalable tools for early identification of individuals at risk, enabling personalized assessment and timely DMT administration.\n\nObjectives:\n\n* Evaluate the accuracy of innovative, easily accessible biomarkers in predicting biologically confirmed AD.\n* Assess the predictive utility of previously studied methods for SCD patients.\n* Explore new approaches, including automated speech analysis, to identify cognitive decline.\n* Evaluate genetic contributions to AD risk.\n* Integrate data from these various modalities using machine learning to create a predictive model for AD in SCD patients.\n\nStudy Design:\n\nThis is a multicenter, longitudinal, low-intervention study conducted at IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy (UO1) and the Center for Research and Innovation in Dementia, Careggi Hospital, Florence, Italy (UO2). Eligible participants are adults with SCD, intact daily functioning, and Mini-Mental State Examination (MMSE) scores \\>24. Exclusion criteria include neurological or systemic diseases, major psychiatric disorders, substance use, or prior head injury.\n\nParticipants undergo:\n\n* Detailed medical and family history collection.\n* Comprehensive neuropsychological, personality, and independence in daily activities assessment\n* EEG recording in resting state.\n* Blood sampling for plasma biomarkers (Aβ42, Aβ40, p-tau181, p-tau217, t-tau, NfL, GFAP).\n* CSF biomarker analysis (Aβ42, Aβ40, p-tau, t-tau).\n* Genetic analysis of AD-related genes (PSEN1, PSEN2, APOE, TREM2, ABCA7, BDNF, HTT).\n* Speech recording and analysis using standardized tasks to extract features for automated evaluation.\n\nThe study expects to create a machine learning-based predictive model combining biomarker, neuropsychological, EEG, speech, and genetic data to improve early detection and guide personalized patient care.\n\nProcedures:\n\n* Neuropsychological evaluations occur at baseline and two-year follow-up.\n* Language recordings are conducted in controlled settings using standardized picture description tasks.\n* EEG is recorded using 21-channel systems.\n* Blood and CSF samples are collected, processed, and stored at -80°C for subsequent analysis at respective institutional laboratories.\n* Plasma biomarkers are analyzed with Simoa technology; CSF biomarkers are analyzed using chemiluminescent enzyme immunoassay (CLEIA).\n* Genetic analyses employ PCR, high-resolution melting analysis (HRMA), sequencing, and capillary electrophoresis as appropriate for specific genes or polymorphisms.\n\nThe study expects to create a machine learning-based predictive model combining biomarker, neuropsychological, EEG, speech, and genetic data to improve early detection and guide personalized patient care.",[69,100,30,101,102,103],"Subjective Cognitive Complaints (SCCs)","Subjective Cognitive Concerns","Subjective Memory Complaint","Subjective Memory Decline",[105,106,107,108,109,110],"Alzheimer","Neuropsychology","EEG","Machine Learning","Biomarkers","Speech","2026-02-03",{"date":113,"type":48},"2026-02-11",{"date":115,"type":48},"2025-10-01",{"date":117,"type":23},"2028-03-01",{"name":119,"class":55},"IRCCS Policlinico S. Donato",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":131,"conditions":132,"keywords":141,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100316694","comprehensive-assessment-of-neurodegeneration-and-dementia-100316694","NCT03402919","Comprehensive Assessment of Neurodegeneration and Dementia","The Comprehensive Assessment of Neurodegeneration and Dementia Study","COMPASS-ND","Inclusion Criteria:\n\n* Has subjective or objective cognitive impairment\n* Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from a caregiver\u002Ffamily member)\n* Sufficient proficiency in English or French to undertake self report and neuropsychological testing\n* Geographic accessibility to the study site\n* Must have a study partner who can participate as required in the protocol (provide corroborative information)\n* Up to 12 years of education\n* Fits into one of the following groups: Cognitively Unimpaired, Subjective Cognitive Impairment, Mild Cognitive Impairment, Vascular Mild Cognitive Impairment, Parkinson's Disease, Parkinson's Disease with Mild Cognitive Impairment\n\nExclusion Criteria:\n\n* The presence of other significant known chronic brain disease such as: moderate to severe chronic static leukoencephalopathy (including previous traumatic injury), multiple sclerosis, a serious developmental handicap, malignant tumors, Parkinson's disease (other than for the Parkinson's cohort), and other rarer brain illnesses\n* Ongoing alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures\n* Symptomatic stroke within the previous year\n* Unable to undergo MRI scan due to medical contraindications or inability to tolerate the procedure","90 Years",{"count":130,"type":23},1573,"This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits. Participants are\u002Fwill be recruited at sites across Canada and will undergo assessments, neuroimaging, and biological sample collection.",[133,134,30,135,136,137,138,139,140,69],"Dementia","Mild Cognitive Impairment (MCI)","Parkinson's Disease (PD)","Lewy Body Disease(LBD)","Mixed Dementia","Frontotemporal Dementia (FTD)","Alzheimer Disease (AD)","Cognitively Unimpaired",[142,133,143,144,145,146,147,74,148,149],"Observational","Alzheimer's Disease","Parkinson's Disease","Biosample","Genetics","Neuropsychological","Microbiome","Plasma","2026-01-15",{"date":152,"type":48},"2026-01-20",{"date":154,"type":48},"2016-06",{"date":156,"type":23},"2029-12",{"name":158,"class":55},"McGill University",19,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":24,"phases":169,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":56},"100603763","a-study-evaluating-the-impact-of-p-tau217-blood-biomarker-testing-on-early-evaluation-and-management-of-patients-presenting-with-cognitive-complaint-100603763","NCT07140744","A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint","A Prospective Diagnostic Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint in Primary and Secondary\u002FTertiary Care","Inclusion Criteria:\n\nHealth Care Provider (HCP) Definitions\n\n* Primary care physician (PCPs): physicians such as family medicine practitioners and internists who do not specialize in neurological care.\n* Secondary care physicians (SCPs): physicians such as geriatricians or neurologists who see patients for specific reasons.\n* Tertiary care physicians (TCPs): specialty neurologists who focus on certain neurological conditions.\n\nHCP Participant Selection Criteria\n\n* HCP inclusion criterion for each category of HCP is as follows:\n\n  * Group 1: PCPs who routinely evaluate and manage patients over the age of 50 in a family practice or internist setting.\n  * Group 2: SCPs and TCPs with experience diagnosing and treating patients with cognitive impairment and dementia.\n\nAdditional inclusion criteria applying to HCPs in the interventional group:\n\n* Must be willing to review educational materials provided by the study sponsor, before enrolling patients.\n\nPatient Participant Criteria\n\n* Participants in the interventional group are eligible to be included in the study only if all the following criteria apply:\n\n  * Are capable of giving, and have given, signed informed consent.\n  * Have venous access sufficient to allow the protocol-required blood sampling.\n  * Are reliable, willing, and able to make themselves available for the duration of the study and are willing to follow study procedures.\n\nDisease-specific Characteristics\n\n* Present to the HCP with 1 or more subjective cognitive impairment complaints (SCIC) in the 4 weeks prior to identification: for example, worsening of memory, misplacing items, difficulty concentrating, or new challenges with problem solving.\n\nPatient Participant Exclusion Criteria:\n\n* In the 18 months prior to identification have prior or associated HCP-ordered referral or prior prescription of drug therapies, for the SCIC\n* Participants with previous amyloid- or tau-specific tests, defined as\n\n  * Amyloid position emission tomography (PET)\n  * Tau PET\n  * Cerebral spinal fluid (CSF) tests for amyloid beta (Aβ) and\u002For tau biomarkers, or\n  * Blood tests for Aβ and\u002For tau biomarkers\n* Has a current serious or unstable illness that in the enrolling investigator's opinion could interfere with completion of the study or have a life expectancy of less than 1 year.\n* Has a known brain lesion, pathology, or prior alternative diagnosis that could explain the participant's clinical presentation.",{"count":168,"type":23},7000,[26],"The purpose of the study is to measure the difference in the proportion of participants with prespecified patient management actions between a tested interventional group and a control group.",[30],[173,174,175],"Diagnostic utility","Blood biomarkers","Blood diagnostics","2025-10-30",{"date":178,"type":48},"2025-11-03",{"date":180,"type":48},"2025-08-22",{"date":182,"type":23},"2027-10",{"name":184,"class":185},"Eli Lilly and Company","INDUSTRY",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":24,"phases":197,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":4},"100584964","comfortage---ad-prevention-strategies-100584964","NCT06896201","Comfortage - AD Prevention Strategies","Comfortage - Integration of Biomarkers, Genetic and Clinical Risk Factors for AD Prevention Strategies","Comfortage-P4","Inclusion Criteria:\n\n* subjective cognitive decline, defined as self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event; normal performance on standardised cognitive tests adjusted for age, sex, and education; decline cannot be explained by psychiatric or other neurologic disease, medical disorder, medication, or substance use; no functional impact on daily life activities\n* mild cognitive decline, defined as persistent decline in cognitive performance (in comparison with a previous status) reported by the subject or by an informed caregiver; or observed by change on longitudinal cognitive testing; cognitive performance below expected range for that individual based on cognitive test performance (adjusted for age, sex, and education); performs daily life activities independently (but cognitive difficulty may result in detectable but minimal functional impact on the more complex activities of daily life, either self-reported or corroborated by a study partner); Clinical Dementia Rating Scale = 0.5\n* Ability to sign and understand the informed consent form\n\nExclusion Criteria:\n\n* Age under 50 or over 85 years\n* Non-native Italian speakers\n* Non degenerative and secondary forms of dementia\n* Previous or current participation in clinical trials with anti-amyloid agents","85 Years",{"count":196,"type":23},200,[26],"Study is Interventional, cross-sectional, clinical trial without drug and without device",[200,30,31],"Alzheimer Disease","2025-08-25",{"date":203,"type":48},"2025-08-26",{"date":205,"type":23},"2025-09",{"date":207,"type":23},"2027-03",{"name":209,"class":55},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":217,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":56},"100527637","sleep-apnea-neurocognitive-decline-and-brain-imaging-in-patients-with-subjective-or-mild-cognitive-impairment-100527637","NCT06150352","Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment","Exploring the Association Between Cognitive Function, Obstructive Sleep Apnea and Brain Imaging, and the Determinants of Neurocognitive Decline in Subjects With Subjective or Mild Cognitive Impairment","Inclusion Criteria:\n\n* Aged 50 - 80 years\n* Diagnosis of mild cognitive impairment based on Peterson's criteria.\n* Diagnosis of subjective cognitive impairment, based on the subjective complaint of cognitive impairment, but with an unremarkable assessment of the Hong Kong version of Montreal cognitive Assessment scores\n* Able to speak and read Chinese\n* Adequate visual and auditory to perform a cognitive test\n* Subjects with moderate-severe OSA or No OSA (diagnosis based on sleep study) would be invited for baseline PET-MRI brain scan\n\nExclusion Criteria:\n\n* Diagnosed psychiatric illness with or without medication, e.g. major depressive disorder.\n* Other clear organic causes of cognitive impairment, e.g. vascular cognitive impairment, brain tumour, dementia with Lewy body, mild cognitive impairment with Lewy body, Parkinson's disease, normal pressure hydrocephalus, neurosyphilis, autoimmune encephalitis, substance abuse, history of alcohol abuse.\n* Diagnosis of cancer on active treatment\n* Contraindications to PET-CT or MRI brain scan (excluded for neuroimaging studies)",{"count":218,"type":23},180,"Obstructive sleep apnea (OSA) is recurrent episodes of partial or complete obstruction of the upper airway during sleep that causes intermittent hypoxia and sleep fragmentation and potentially lead to cardiometabolic and neurocognitive sequelae. Chronic intermittent hypoxia, sleep fragmentation of OSA, and insufficient sleep have been significantly associated with higher risks of neurocognitive impairment, including mild cognitive impairment (MCI) and Alzheimer's disease. Thus, sleep and sleep apnea might be modifiable factors to neurocognitive impairment.\n\nPositive airway pressure (PAP) is the first line of treatment to maintain open airways for patients with OSA. Improving sleep, sleep apnea and circadian function could be a high-value intervention target to alleviate cognitive impairment and decline in subjects with mild neurocognitive impairment.\n\nAmyloid accumulation in brain tissue is a distinct feature of Alzheimers' disease, which is associated with potential impairment of neurocognition clinically. It predicts memory decline in initially cognitively unimpaired individuals.\n\nThe study explores the associations between sleep apnea, cognitive function and cerebral imaging and the role of PAP therapy on neurocognitive trajectory in these patients with subjective cognitive impairment \u002Fmild cognitive impairment (SCI\u002FMCI).",[221,31,30],"Obstructive Sleep Apnea",[223,224,225],"Obstructive sleep apnea","Neurocognitive function","CPAP","2025-03-27",{"date":228,"type":48},"2025-04-02",{"date":230,"type":48},"2023-09-26",{"date":232,"type":23},"2027-03-31",{"name":234,"class":55},"The University of Hong Kong",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":17,"sex":18,"minAge":94,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":249,"locationsCount":56},"100522936","sleep-apnea-and-cognitive-function-in-subjects-with-subjective-or-mild-cognitive-impairment-100522936","NCT06089096","Sleep Apnea and Cognitive Function in Subjects With Subjective or Mild Cognitive Impairment","Exploring the Association of Sleep Apnea With Cognitive Function in Subjects With Subjective or Mild Cognitive Impairment","Inclusion Criteria:\n\n* Aged 18 years and above\n* Clinical diagnosis of mild cognitive impairment (MCI) based on Petersen's criteria. The criteria include the following: (1) memory problems, (2) objective memory disorder, (3) absence of other cognitive disorders or repercussions on daily life, (4) normal general cognitive function and (5) absence of dementia OR,\n* Diagnosis of subjective cognitive impairment, based on the subject's own complaint of cognitive impairment but with an unremarkable assessment of the Hong Kong version of Montreal Cognitive Assessment scores\n* Able to speak and read Chinese\n* Adequate visual and auditory to perform a cognitive test\n\nExclusion Criteria:\n\n* Diagnosed psychiatric illness with or without medication, e.g. major depressive disorder.\n* Other clear organic causes of cognitive impairment, e.g. old stroke, brain tumour, dementia with Lewy body, Parkinson's disease, normal pressure hydrocephalus, neurosyphilis, autoimmune encephalitis, substance abuse, history of alcohol abuse.\n* Diagnosis of major unstable illness or cancer on active treatment\n* Unable to perform Home Sleep Apnea Test\n* Those patients who require legal guardians",{"count":96,"type":23},"Obstructive sleep apnea (OSA) is recurrent episodes of partial or complete obstruction of the upper airway during sleep that causes intermittent hypoxia and sleep fragmentation and leads to cardiometabolic and neurocognitive sequelae. Chronic intermittent hypoxia, sleep fragmentation of OSA, and insufficient sleep have been significantly associated with higher risks of neurocognitive impairment, including mild cognitive impairment (MCI) and Alzheimer's disease. Thus, sleep and circadian function might be modifiable neurocognitive impairment factors.\n\nThe significance of the study is to understand the relationships of MCI with sleep apnea and sleep-related symptoms, which helps pave the groundwork for further research.",[221,31,30],{"date":228,"type":48},{"date":247,"type":48},"2023-03-07",{"date":232,"type":23},{"name":234,"class":55},{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":17,"sex":18,"minAge":257,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":261,"conditions":262,"keywords":266,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":282},"100507909","uppsala-dalarna-dementia-and-gait-project-100507909","NCT05893524","Uppsala-Dalarna Dementia and Gait Project","UDDGait™","Inclusion Criteria:\n\n* Patients undergoing memory assessment at at Uppsala University Hospital, Sweden\n* Patients undergoing memory assessment at at Falu Hospital, Sweden\n* Cognitively unimpaired individuals with a Mini Mental State Examination (MMSE) score of \\> 26\n\nExclusion Criteria:\n\n* Inability to walk three meters back and forth\n* Inability to rise from a sitting position\n* Indoor use of a walking aid\n* Current or recent hospitalization (within the last 2 weeks)\n* Need of an interpreter to communicate in Swedish","37 Years","94 Years",{"count":260,"type":23},550,"UDDGait™ is a multidisciplinary research project with the overreaching goal of providing an aid for early identification of cognitive impairment and risk of dementia development, thereby providing a basis for adequate symptom relieving and health promoting interventions.\n\nA new concept is investigated for this purpose: a \"dual-task-test\", which implies the combination of a well-established mobility test (Timed Up-and-Go, TUG) with a simultaneous verbal task (i.e. TUG dual-task, TUGdt). This type of test has been judged as a potential aid for early identification of dementia disease. More research is needed to further examine the test's validity, reliability and predictive capacity.\n\nThe overall aim is to investigate if TUGdt is useful as an aid for prediction of dementia disease. To ensure the results, the aim is also to evaluate the test's measurement properties and to generate normative reference values of healthy control persons.",[133,263,264,265,31,30],"Dementia, Mixed","Dementia Senile","Dementia of Alzheimer Type",[267,268,269,133,31,30,270,271,272],"Timed Up-and-Go, TUG","TUG dual-task","Cognitive tests","Alzheimer's disease","Step parameters","Video recorded tests","2025-02-11",{"date":275,"type":48},"2025-02-12",{"date":277,"type":48},"2015-04-09",{"date":279,"type":23},"2026-12-24",{"name":281,"class":55},"Dalarna University",2,{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":18,"minAge":290,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":24,"phases":293,"briefSummary":294,"conditions":295,"keywords":297,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":312},"100578861","testing-the-cog-fun-aging-program-for-older-adults-with-subjective-cognitive-decline-100578861","NCT06816797","Testing the Cog-Fun Aging Program for Older Adults With Subjective Cognitive Decline","Efficacy of the Cog-Fun Aging Health Promotion Intervention for Older Adults With Subjective Cognitive Decline: A Pilot Controlled Study","Inclusion Criteria:\n\n* experiencing memory changes and feeling concerned about them\n* a score of 23 or higher on the MoCA (Montreal Cognitive Assessment)\n* ability to speak and understand Hebrew sufficiently to participate in a Hebrew-speaking group\n\nExclusion Criteria:\n\n* a self-reported health condition that significantly impacts functioning (e.g., uncontrolled diabetes, severe heart\u002Flung disease)\n* residing in a medical institution or nursing home\n* currently participating in another SCD treatment","60 Years",{"count":292,"type":23},40,[26],"The goal of this clinical trial is to learn if the Cog-Fun Aging program helps older adults with Subjective Cognitive Decline (SCD) manage memory challenges and improve their daily lives. The main questions it aims to answer are:\n\n* Does the program help participants better understand their cognitive challenges in daily life?\n* Do participants report using more effective strategies to manage their memory difficulties?\n* Does the Cog-Fun Aging program reduce negative emotions and self-perceptions related to SCD?\n\nResearchers will compare participants who complete the Cog-Fun Aging program with those who do not to determine the program's effectiveness.\n\nParticipants will:\n\nTake part in a 10-week program with weekly sessions. Learn about SCD and how it affects daily life. Practice and monitor strategies to manage memory difficulties.",[69,30,296],"Subjective Memory Complaints",[298,299,300,301,302,303],"negative self perceptions","cognitive mistakes","occupational experience","occupational therapy","subjective cognitive decline","health promotion intervention","2025-02-08",{"date":275,"type":48},{"date":307,"type":48},"2024-11-20",{"date":309,"type":23},"2025-08",{"name":311,"class":55},"Hebrew University of Jerusalem",3,{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":24,"phases":322,"briefSummary":323,"conditions":324,"keywords":326,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":56},"100520595","effects-of-a-computerised-cognitive-stimulation-versus-stimulating-leisure-activities-100520595","NCT06058611","Effects of a Computerised Cognitive Stimulation Versus Stimulating Leisure Activities","Effects of a Personalised and Tailored Computerised Cognitive Stimulation Programme Versus Stimulating Leisure Activities in Older Adults with Mild Cognitive Impairment and Subjective Cognitive Impairment: Randomised Controlled Trial","Inclusion Criteria:\n\n* ≥ 50 years old, resident in the community.\n* Diagnosis of MCI or having between 24 and 27 points on the MEC-35 (this score seems to indicate the presence of MCI) (Calero, M. D and Navarro, 2006).\n* Subjective cognitive impairment (score between 28-31 points on the MEC-35) (Gómez-Soria et al. 2023)\n\nExclusion Criteria:\n\n* Institutionalisation.\n* Taking acetylcholinesterase inhibitors as they may act on global cognition and\u002For cognitive functions.\n* Sensory deficits (deafness and blindness) preventing intervention.\n* Agitation.\n* Having received cognitive stimulation in the last 12 months.",{"count":321,"type":23},90,[26],"The aim of the study is to evaluate, at the level of global cognition, cognitive neuroconstructs, memory, verbal fluency, ADLs, IADLs, symptoms of depression and anxiety, the effectiveness of a personalised and adapted computerised cognitive stimulation programme (GI1) implemented from Primary Care versus stimulating leisure activities (GI2), in older adults aged 50 years and over with mild cognitive impairment and subjective cognitive impairment living in the community.",[31,325,30],"Randomized Controlled Trial",[31,327,328,325,329,330,331,332,30],"Older adults","Elderly","Cognitive Stimulation","Cognitive Intervention","Cognitively Stimulating Leisure Activities","Leisure Activities","2024-12-06",{"date":335,"type":48},"2024-12-12",{"date":337,"type":48},"2024-04-01",{"date":339,"type":23},"2025-09-30",{"name":341,"class":55},"Universidad de Zaragoza",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":63,"enrollmentInfo":350,"targetDuration":4,"studyType":24,"phases":352,"briefSummary":353,"conditions":354,"keywords":355,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":312},"100480332","natives-engaged-in-alzheimers-research---ike-kupuna-100480332","NCT05534607","Natives Engaged in Alzheimers Research - 'Ike Kupuna","Natives Engaged in Alzheimers Research - 'Ike Kupuna (Elder Wisdom) Project","NEAR","Inclusion Criteria:\n\n1. self-reported Native Hawaiian or other Pacific Islander ancestry;\n2. ages 50+ but not older than 75 (optimal age range for preventing future dementia in people with cognitive impairment, above 75 is not likely to benefit from this study given their advance age);\n3. has subjective cognitive impairment (SCI) or mild cognitive impairment (MCI);\n4. have a diagnosis of hypertension, diabetes, dyslipidemia, or obesity (body-mass-index ≥ 30 kg\u002Fm2);\n5. physically able and willing to engage in moderate physical activity necessary for Hula; and\n6. physician's approval to participate in moderate physical activity\n\nExclusion Criteria:\n\n1. currently pregnant;\n2. already actively practicing Hula at least once per week; or\n3. clinical diagnosis of ADRD (mild to severe); or\n4. current diagnosed major depressive disorder at moderate or greater stage, or moderate or greater depression on the Center for Epidemiological Studies Depression Scale (CES-D).",{"count":351,"type":23},192,[26],"This study will conduct a group randomized trial to test the effects of a hula-based intervention in improving vascular risk factors for ADRD and cognitive complaints and function over 12 months.",[31,30],[356,270,357,358,359,360,361,362,363,364,365],"MCI","Alzheimer's disease and related dementias","Vascular dementia","ADRD","SCI","Native Hawaiian and Pacific Islander","NHPI","Hula","cultural based intervention","behavioral intervention","2024-07-30",{"date":368,"type":48},"2024-08-01",{"date":370,"type":48},"2022-09-15",{"date":372,"type":23},"2027-04-30",{"name":374,"class":55},"University of Hawaii",{"id":376,"slug":377,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":17,"sex":18,"minAge":290,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":24,"phases":384,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":56},"100516478","phase-1-cogt-psopt-intervention-study-100516478","NCT06005038","CogT pSOPT Intervention Study","Personalized Engine for Speed of Information Processing","Inclusion Criteria:\n\n1. criteria related to defining \"mild cognitive impairment\": a. Presence of memory complaint; b. Rey Auditory Verbal Learning Test delayed recall (for memory) \\\u003C 59% of age-adjusted norm; c. Montreal Cognitive Assessment (for global cognition) ranged 18 and 27; d. Functional Assessment Questionnaire (for activities of daily living) \\\u003C 20.\n2. intact score for San Diego Brief Assessment of Capacity to Consent (UBACC).\n3. if a participant is on AD medication (i.e., memantine, cholinesterase inhibitors, amyloid antibodies), antidepressants, anxiolytics, or vascular risk or diseases related medications (e.g., beta-blocker), the dose should be stable for 3 months prior to recruitment.\n4. age 60+,\n5. read and understand English\n6. adequate visual and hearing acuity for testing by self-report,\n7. community-dwelling (including independent living).\n\nExclusion Criteria:\n\n1. current enrollment in another cognitive improvement study;\n2. uncontrollable major depression;\n3. major cerebrovascular and cardiovascular diseases (e.g., congestive heart failure, pacemaker, prior myocardial infarction);\n4. having an active legal guardian (indicating impaired capacity for decision making);\n5. currently pregnant\n6. 3T MRI contraindication\n7. Neurological conditions: Neurodegenerative disease diagnosis such as Parkinson's, Alzheimers, dementia, multiple sclerosis. Of note, other neurological conditions\u002Finjury such as stroke, seizures, traumatic brain injury, will be evaluated for inclusion\u002Fexclusion on a case-by-case basis based on event recency, severity, and recovery.",{"count":383,"type":23},50,[385],"PHASE1","(JUSTIFICATION: This is the R33 stage of an NIH funded R21\u002FR33 study. R21 stage (IRB-61727) was focused on intervention development; R33 stage will focus on pilot testing the effect of the intervention. The R21 phase was not considered a NIH defined clinical trial; R33 will be considered a NIH defined clinical trial)\n\nThe purpose is to develop and test the effect of a \"personalized\" computer-based cognitive training program. The personalized program tailors the difficulty of the training tasks using a participant's biofeedback (i.e., heart rate) and cognitive performance. Such a personalization will ensure that the participant can perform at his\u002Fher ideal training capacity. Participants will be randomized into one of 2 groups and each group will play a different version of computerized training game and have ECG collected to allow subject blinding.",[31,30],"2024-05-16",{"date":390,"type":48},"2024-05-17",{"date":392,"type":48},"2024-01-12",{"date":394,"type":23},"2026-12-31",{"name":396,"class":55},"Stanford University",{"id":398,"slug":399,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":17,"sex":18,"minAge":290,"maxAge":194,"enrollmentInfo":404,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":406,"conditions":407,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":56},"100287339","gait-as-predictor-of-dementia-and-falls-the-gait-and-brain-cohort-study-100287339","NCT03020381","Gait as Predictor of Dementia and Falls. The Gait and Brain Cohort Study","Gait as Predictor of Cognitive Decline, Dementia, and Risk of Falls in MCI. A Cohort Study","General Inclusion Criteria:\n\n* Absence of Dementia (DSM IV-TR or DSM V criteria)\n* Aged 60-85 years\n* Able to walk independently 10 meters without any gait aid (for example: walker, cane);\n\nExclusion Criteria:\n\n* Unable to understand English;\n* Parkinsonism or any neurological disorder with residual motor deficit (e.g.: stroke, epilepsy);\n* Musculoskeletal disorder detected by clinical examination which affects gait performance;\n* Active osteoarthritis affecting the lower limbs at clinical evaluation\n* Use of psychotropics which can affect motor performance (e.g. neuroleptics and benzodiazepines)\n* Severe Depression (score \\> 12\u002F15 on the Geriatric Depression Scale).",{"count":405,"type":23},600,"Motor slowing and cognitive slowing are more prevalent as we age. Importantly, the presence of both in an older person increases their risk of having dementia by ten times. Currently, there are no clinically meaningful predictors of progression to dementia in people with mild cognitive impairment (MCI). The main hypothesis is that subtle variations in gait while performing a simple cognitive task is a reliable, easy to perform, and feasible methodology to detect those older adults at higher risk of progression to dementia and also, at higher risk of further mobility decline and falls.\n\nRationale. The Canadian population is aging. According to recent estimates, the proportion of the population aged 65 and older will increase rapidly from 13% in 2005 to 25% by 2031. This increase in proportion is accompanied by a considerable amount of disability and subsequent dependency which has major effects on both the quality of life of older adults and their caregivers, and on the Canadian health care system. An important goal of geriatric medicine is to reduce the gap between life expectancy and disability-free life expectancy by reducing disability and dependency in the later years of life. A substantial portion of this disability stems from two major geriatric syndromes: cognitive impairment and mobility limitation. The ultimate manifestations of these syndromes are dementia and falls. Interestingly, these manifestations often coexist in elderly people: falling is a common geriatric syndrome affecting about a third of older adults each year, and dementia affects about a third of Canadians aged 80 and over. Together, dementia and falls are responsible for much of the discomfort, disability, and health care utilization in older adults and each will become more prevalent as older Canadians are expected to number approximately $9 million by 2031. The combined direct cost of dementia and falls for the Canadian Health System is over $4.9 billion per year.\n\nEstablishing reliable and easy to obtain predictors to accurately identify MCI patients at highest risk of progressing to dementia is essential first, to determine who will benefit from additional and\u002For invasive testing and second, to implement preventative strategies, including cognitive training, physical exercises, and aggressive vascular risk factors correction to delay progression. Even a modest one-year delay in dementia incidence could save Canada $109 billion over 30 years.",[408,31,30,409,200,133],"Gait Apraxia","Cerebral Atrophy","2023-12-15",{"date":412,"type":48},"2023-12-21",{"date":414,"type":4},"2007-12",{"date":416,"type":23},"2033-01",{"name":418,"class":55},"Manuel Montero Odasso",{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":18,"minAge":290,"maxAge":63,"enrollmentInfo":426,"targetDuration":4,"studyType":24,"phases":428,"briefSummary":429,"conditions":430,"keywords":431,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":56},"100476522","long-term-prospective-study-of-tai-chi-intervention-to-delay-the-progression-of-subjective-cognitive-impairment-100476522","NCT05485025","Long Term Prospective Study of Tai Chi Intervention to Delay the Progression of Subjective Cognitive Impairment","TIPS","Inclusion Criteria:\n\n1. Male and female participants aged 60 to 75 years (inclusive) at the time of screening;\n2. Willing and able to give informed consent by GCP and local guidance;\n3. Meets the diagnostic criteria for subjective cognitive impairment (SCI) and the following criteria\n\n   * Subjective decline in memory, rather than other domains of cognition\n   * Onset of SCI within the last 5 y\n   * Concerns (worries) associated with SCI\n   * Feeling of worse performance than others of the same age group\n   * Confirmation of cognitive decline by an informant.\n4. Have the physical, cognitive, listening, speech, literacy and language skills necessary to participate in all tests;\n5. Capable of performing MR.\n\nExclusion Criteria:\n\n1. Cognitive impairment caused by other reasons (for example) cerebrovascular disease, central nervous system infection, Creutzfeldt-Jakob disease, Huntington's disease, Parkinson's disease, dementia with Lewy bodies, trauma, other physical and chemical factors (drugs, alcohol, CO, etc.), important physical diseases (hepatic encephalopathy, pulmonary encephalopathy, etc.), brain tumor, endocrine diseases (thyroid disease, parathyroid disease), and vitamin deficiency or any other cause of dementia;\n2. Abnormal folate, thyroid, and\u002For vitamin B12 values that cannot be corrected before baseline visit;\n3. Major structural brain disease as judged by central MRI Diagnostic Imaging Review Team (eg, ischemic infarcts, subdural hematoma, hemorrhage, hydrocephalus, brain tumors, multiple subcortical ischemic lesions. or a single lesion in a critical region \\[eg, thalamus\\]). Mild white matter changes without clinical significance and no more than 2 lacunar infarcts are permitted;\n4. Geriatric Depression Scale-15(GDS-15) total score \\> 7 at screening;\n5. MOCA\\\u003C26 points;\n6. CDR global score \\>0;\n7. Hachinski ischemia score \\>4;\n8. During the clinical study, the following drugs are prohibited:\n\n   Acetylcholinesterase inhibitors, N-methyl-D-aspartate (NMDA) antagonists (eg, memantine), central nervous system stimulants, and various medicines that can improve memory or cognition; Antipsychotics\n9. Mental illness determined by Diagnostic and Statistical Manual of Mental Disorders (DSM) V criteria, that is unstable within 12 months, or would interfere with study assessments, including schizophrenia or other psychotic disorders, bipolar disorder, severe depression, or delirium.\n10. DSM V diagnosis of alcohol or other substance abuse dependence within the last 12 months.\n11. History or current diagnosis of significant cardiac arrhythmias, myocardial infarction, transient ischemic attack, or cerebrovascular accident, uncompensated congestive heart failure New York Heart Association class III and IV.\n12. Major medical illness or unstable medical condition within 6 months of screening that in the opinion of the investigator may interfere with the participant's ability to comply with study procedures and abide by study restrictions, or with the ability to interpret safety data, including any physical disability (eg. blindness. deafness, non-cognitive related speech impairment, sensory or motor dysfunction) that would prevent completion of study procedures or assessments.\n13. Cancer except:\n\n    History of any cancer that has been in remission (no evidence of recurrence) for \\> 5 years from the screening Participants with basal cell or stage I squamous cell carcinoma of the skin, stable untreated cancer as prostate or meningioma.\n14. Active physical activity for 6 months prior to screening.\n15. Participants are excluded if they\n\n    1. have participated in any other clinical study within 4 weeks prior to screening visit\n    2. have participated in another Tai chi clinical study at any time\n    3. plan to take part in another clinical study during this study.\n16. The researcher estimates that the subject's compliance is poor, and it is believed that the subject is unlikely to complete the study.",{"count":427,"type":23},134,[26],"This study evaluates the effects of 3 years-Tai Chi exercise intervention on cognitive function in subjects with subjective cognitive impairment (SCI). Participants will be randomized into the Tai chi training group and the control group.",[30],[432,433],"subjective cognitive impairment","Tai Chi","2022-07-30",{"date":436,"type":48},"2022-08-02",{"date":438,"type":23},"2022-09",{"date":440,"type":23},"2026-09",{"name":442,"class":55},"Ruijin Hospital"]